Cardiovascular Revascularization Medicine最新文献

{"title":"Left atrial appendage occlusion in patients with amyloidosis: a nationwide cohort analysis","authors":"Akiva Rosenzveig, Shashank Shekhar, Shady Nakhla, Andrew Higgins, Amar Krishnaswamy, Samir Kapadia, Grant W. Reed","doi":"10.1016/j.carrev.2024.10.012","DOIUrl":"10.1016/j.carrev.2024.10.012","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"72 ","pages":"Pages 64-65"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early CABG with intraoperative hemoadsorption in patients on ticagrelor: Real world data from the international Safe and Timely Antithrombotic Removal (STAR) registry.","authors":"Robert F Storey, Kambiz Hassan, Anna L Meyer, Thomas Eberle, Nikolaas deNeve, Matthias Thielmann, Martin H Bernardi, Nandor Marczin, Ulf Guenther, Bernd Panholzer, Heinrich Maechler, Steven Hunter, Marijana Matejic-Spasic, Daniel Wendt, Efthymios N Deliargyris, Michael Schmoeckel","doi":"10.1016/j.carrev.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.015","url":null,"abstract":"<p><strong>Objectives: </strong>Severe perioperative bleeding occurs in over 30 % of patients on ticagrelor undergoing isolated coronary artery bypass grafting (i-CABG) before completing the recommended 3-day washout. Intraoperative ticagrelor removal with a polymer bead hemoadsorption device is an approved therapy that may reduce perioperative bleeding.</p><p><strong>Methods: </strong>The current analysis from the international Safe and Timely Antithrombotic Removal (STAR) registry reports outcomes with intraoperative hemoadsorption in patients on ticagrelor undergoing i-CABG before completing the recommended washout. Bleeding was assessed by the Universal Definition of Perioperative Bleeding (UDPB) definition.</p><p><strong>Results: </strong>102 patients (63.8 ± 10.1 years, 81.2 % male) underwent i-CABG at mean time from last dose (TLD) of 22.8 ± 14.6 h. Groups were created based on TLD to CABG: Group-1 (G1): <24 h (n = 61; TLD 12.6 ± 6.5 h); Group-2 (G2): 24-72 h (n = 41; 37.2 ± 10.1 h). G1 was higher risk than G2 based on EuroSCORE-II (median: 4.2 % vs. 1.7 %, p = 0.006) and emergency indication (66.1 % vs. 12.2 %, p < 0.001). Operation and cardiopulmonary bypass durations were similar (G1: 4.3 ± 1.5 h and 94.9 ± 37.1 min vs. G2: 4.4 ± 1 h and 94.7 ± 36.1 min, p = ns). Severe bleeding (UDPB≥3) and re-operations for bleeding were more frequent in G1 vs. G2 (14.8 % vs. 2.4 %, p = 0.047, and 8.2 % vs. 0 %, p = 0.08, respectively). Any transfusion of red blood cells or platelets was also more frequent in G1 vs. G2 (45.9 % vs. 26.8 %, p = 0.05 and 59.0 % vs. 34.1 %, p = 0.014, respectively).</p><p><strong>Conclusions: </strong>Intraoperative ticagrelor removal may help reduce ticagrelor-related bleeding in patients undergoing i-CABG before completing the 3-day washout. High risk emergency procedures within the first 24 h of last ticagrelor dose have an increased bleeding risk.</p><p><strong>Clinical trial registry number: </strong>ClinicalTrials.gov: NCT05077124.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paclitaxel crystal visualization by intravascular imaging following drug-coated balloon angioplasty: A report of 2 cases.","authors":"Rajesh Vijayvergiya, Arghadip Bose, Nikhil Sharma, Basant Kumar, Bhupinder K Sihag, Ankush Gupta","doi":"10.1016/j.carrev.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.013","url":null,"abstract":"<p><p>Drug-coated balloons (DCB) have evolved as an alternative to drug-eluting stents in coronary interventions without the addition of an extra metal layer while delivering antiproliferative drugs. However, the delivery of the drug at the target site cannot be objectively assessed in routine practice. Hence, the success of a DCB angioplasty is limited to luminal gain alone. We report a novel finding of tiny paclitaxel crystals detected on the intimal surface by intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in two cases treated with DCB angioplasty.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete revascularization in elderly patients with multi-vessel disease following acute coronary syndrome: A multicenter retrospective study.","authors":"António Rocha de Almeida, Rafael Viana, Kisa Congo, Manuel Trinca, Lino Patrício","doi":"10.1016/j.carrev.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.009","url":null,"abstract":"<p><strong>Background: </strong>In the elderly, acute coronary syndromes (ACS) are particularly challenging, especially with multivessel disease (MVD). Concerns about outcomes and limited evidence often lead to conservative treatment. While complete revascularization benefits in younger patients are well established, uncertainties persist for older individuals.</p><p><strong>Methods: </strong>A national multicenter, retrospective cohort study of 629 patients older than 75 with ACS and MVD was divided into two groups: complete revascularization (CR) and culprit-only (CO) revascularization. The in-hospital composite outcome of death and major adverse cardiovascular events (MACE) and the follow-up composite outcome of death and cardiovascular hospital admission were assessed.</p><p><strong>Results: </strong>Of 629 patients, 383 (66 %) were successfully revascularized: 254 (66 %) with CO revascularization and 129 (34 %) with CR. The mean age between groups was similar; in the CO group, it was 82 ± 5 years, while in the CR group, it was 81 ± 5 years (p = 0.4). The proportion of females was similar (42 % vs. 39 %). There was a higher ST-segment elevation myocardial infarction rate in the CO group (62 % vs 38 %, p < 0.01). CR was associated with a lower rate of in-hospital events (35 % vs 51 %, p = 0.025; OR 0.62 95 %CI [0.4-0.9]). Not only was there an association between CR and a lower number of in-hospital deaths (6 % vs. 19 %, p < 0.01; OR 0.3 95 %CI [0.15-0.67]) but also with lower in-hospital MACE (34 % vs. 49 % p = 0.02; OR 0.6 95 %CI [0.4-0.9]). During follow-up, complete revascularization was non-significantly associated with lower mortality (14 % vs. 15 %, p = 0.4), hospital admissions (22 % vs. 25 %, p = 0.2), and the composite outcome (35 % vs. 40 %, p = 0.2) compared with the culprit-only cohort. The survival curves of both groups were statistically similar (p = 0.16).</p><p><strong>Conclusion: </strong>In older patients with ACS and MVD, the ideal revascularization strategy is still to be determined. However, CR was associated with lower in-hospital deaths and MACE without significant difference in follow-up events, deaths, and hospital admissions. The choice of revascularization strategy should be carefully individualized and tailored considering patient-specific factors, clinical presentation, and overall risk profile.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of the BioMime™ morph coronary stent system for long (30 to ≤56 mm length) coronary lesions: Three-year follow-up of the Morpheus Global Registry.","authors":"Pierfrancesco Agostoni, Jan-Peter Van Kuijk, Paul Knaapen, Farhat Fouladvand, Martin Hudec, Antonino Nicosia, Kari Kervinen, Salvatore Davide Tomasello, Ramesh Singh Arjan Singh, Girish N Vishwanathan, Béla Merkely, Houng Bang Liew, Khalid Al Faraidy, Clive Corbett, Saleem Dawood, Anirban Choudhury, Imad Abdelhafiz Alhaddad, Azfar Zaman, Adriaan O Kraaijeveld, Martino Pepe","doi":"10.1016/j.carrev.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.010","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous coronary intervention (PCI) of long coronary artery lesions (CAL) presents a puzzle, often requiring multiple stents. As the arteries twist and narrow, this becomes even more challenging with issues like potential distal overexpansion and proximal under expansion, and edge dissections. The study aims to assess the safety and performance of BioMime™ Morph sirolimus-eluting stent (SES) in individuals with long CAL.</p><p><strong>Methods: </strong>This prospective, single-arm, multi-center, observational, real-world registry, included 565 patients with long CAL (length 30 to ≤56 mm) in native coronary arteries (reference vessel diameters: 2.25 mm to 3.50 mm). Based on lesion length, patients were implanted with 30 mm, 40 mm, 50 mm, or 60 mm BioMime™ Morph SES. Primary endpoint was freedom of target lesion failure (TLF) at 6-month and up to 36-month.</p><p><strong>Results: </strong>Over 65 % of patients had lesions requiring 50 mm and 60 mm stents. The follow-up length was up to 24-month for the whole cohort and up to 36-month only for 211 patients from seven selected centers. The freedom from TLF rate was 97.86 %, 97.26 %, 96.27 %, and 95.15 % at 6-, 12-, 24-, and 36-month follow-ups, respectively. The cumulative rates of major adverse cardiac events (MACE) were 2.74 % at 12-month, 3.73 % at 24-month and 4.85 % at 36-month. Additionally, the rates of ischemia-driven target lesion revascularization were 2.01 % at 12-month, 2.16 % at 24-month, and 3.88 % at 36-month. Lastly, stent thrombosis (ST) was reported in only 2 cases (0.97 %) at 36-month.</p><p><strong>Conclusion: </strong>The lower incidences of MACE and ST up to three-year follow-up indicate BioMime™ Morph SES is an effective and safe option for PCI in long CAL.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term outcomes of transcatheter aortic valve implantation in patients with concomitant mitral or tricuspid regurgitation.","authors":"Shafaqat Ali, Irisha Badu, Manoj Kumar, Thannon Alsaeed, Lalitsiri Atti, Faryal Farooq, Sanchit Duhan, Bijeta Keisham, Pramod Kumar Ponna, Vijaywant Brar, Pratik Agrawal, Mabruka Alfaidi, Yasmin S Hamirani, Tarek Helmy, Timir K Paul","doi":"10.1016/j.carrev.2025.02.008","DOIUrl":"10.1016/j.carrev.2025.02.008","url":null,"abstract":"<p><p>Mitral regurgitation (MR) or tricuspid regurgitation (TR) is often an indicator of poor prognosis in patients with aortic stenosis (AS). Our study aims to compare transcatheter aortic valve implantation (TAVI) outcomes in patients with and without concomitant MR or isolated TR. Using the national readmission database (2016-2020), we identified patients with severe AS undergoing TAVI. We used multivariable regression for adjusted analysis and the Propensity Score Matching (PSM) model. Among 315,163 hospitalizations for TAVI, 14,577 (4.6 %) had concomitant MR, while 3859 (1.2 %) had isolated TR. On PSM, TAVI in concomitant MR was associated with higher acute CHF (50.1 % vs 43.7 %, p-value < 0.001), mechanical circulatory support (MCS) need (1.5 % vs 0.9 %, p-value: 0.001), acute myocardial infarction (5.6 % vs. 4.3 %, p-value < 0.001) and net adverse events (61.5 % vs. 59.2 %, p-value: 0.002) while the mortality difference was not significant (p > 0.05). Higher total costs ($58,104 vs $55,183, p-value < 0.001), 90- (22.8 % vs. 21.2 %), and 180-day readmission rates (32.1 % vs. 29.4 %) were also observed [p-value < 0.05]. Similarly, TAVI in the presence of isolated TR was associated with higher cardiogenic shock (3.2 % vs. 1.8 %, p: 0.004) and MCS need (1.5 % vs 0.7 %, p: 0.009). TAVI with coexisting TR showed higher rates of 30-day (13.4 % vs. 11.2 %), 90-day (26 % vs. 21.2 %), and 180-day (34.3 % vs 29.1 %) readmission rates [p < 0.05]. A higher median length of stay (3 vs. 2 days) and total cost ($60,376 vs. $55,183) [p-value < 0.001] were also observed. TAVI in concomitant MR or TR was associated with higher periprocedural adverse events, increased healthcare burden & readmission rates.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary risk models for transcatheter aortic valve replacement: A narrative review.","authors":"Nicholas Chan, Ankit Agrawal, Aro Daniela Arockiam, Muhammad Majid, Elio Haroun, Aaisha Shah, Rishi Puri, Brian Griffin, Tom Kai Ming Wang","doi":"10.1016/j.carrev.2025.02.011","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.011","url":null,"abstract":"<p><p>Aortic stenosis (AS) is the most common form of valvular heart disease in older adults requiring intervention. Severe symptomatic AS, if left untreated, is typically associated with a poor prognosis. Over the past two decades, there have been significant advances in the field of transcatheter aortic valve replacement (TAVR), leading to its emergence as an alternative to the well-established surgical aortic valve replacement (SAVR) for treating severe AS. Multiple randomized clinical trials have demonstrated comparable efficacy and safety outcomes of TAVR vs SAVR in high, intermediate, and low-risk surgical candidates. In the process, multiple risk scores, both traditional surgical and TAVR-specific, have been developed to better risk stratify patients as well as guide periprocedural management and patient counseling. This review aims to discuss the currently available risk models for risk prediction in TAVR patients, highlighting their strengths, limitations, and applicability to different patient populations.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term clinical efficacy of transfemoral transcatheter aortic valve implantation with three different platforms.","authors":"Elena Dipietro, Giuliano Costa, Mariachiara Calì, Orazio Strazzieri, Silvia Crescenzia Motta, Valentina Frittitta, Alessandro Comis, Sofia Sammartino, Luigi La Rosa, Carmelo Sgroi, Wanda Deste, Pierfrancesco Veroux, Salvatore Lentini, Maria Cristina Inserra, Maria Teresa Cannizzaro, Valeria Garretto, Corrado Tamburino, Marco Barbanti","doi":"10.1016/j.carrev.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.01.014","url":null,"abstract":"<p><strong>Background: </strong>Long-term durability and outcomes of transcatheter aortic valve implantation (TAVI) have been reported only with first generation devices.</p><p><strong>Objectives: </strong>To compare clinical efficacy of TAVI with Sapien 3 (Edwards Lifesciences), Evolut R/PRO (Medtronic) or Acurate Neo (Boston Scientific) transcatheter heart valves (THVs) at long-term.</p><p><strong>Methods: </strong>Consecutive TAVI patients treated with Sapien 3, Evolut R/PRO and Acurate Neo THVs at Policlinico G. Rodolico of Catania with at least 5 years follow-up were included in this analysis. Patients were divided into three different groups according to the TAVI device used. Outcomes were compared after inverse probability of treatment weighting adjustment. The primary endpoint was the composite of all-cause death, disabling stroke and heart failure (HF) re-hospitalization at 7 years. The co-primary endpoint was valve-related clinical efficacy according to Valve Academic Research Consortium 3 (VARC-3) definition, at 7 years.</p><p><strong>Results: </strong>From September 2014 to December 2018, 383 tranfemoral TAVI patients receiving Sapien 3 (n = 131, 34.2 %), Evolut R/PRO (n = 134, 34.9 %), or Acurate Neo (n = 118, 30.8 %) devices were compared. At 7 years, the composite primary endpoint did not differ among study groups (60.2 % vs. 51.6 % vs. 62.1 % for Sapien 3, Evolut R/PRO and Acurate Neo, respectively, p_log-rank = 0.50). The co-primary endpoint was also similar (2.2 % vs. 1.2 % vs. 4.2 %, for Sapien 3, Evolut R/PRO and Acurate Neo, respectively, p_log-rank = 0.86).</p><p><strong>Conclusions: </strong>Clinical efficacy of TAVI with Sapien 3, Evolut R/PRO and Acurate Neo devices was sustained and comparable up to 7 years. Low and similar rates of valve degeneration were reported among the three devices. Randomized clinical trials are necessary to corroborate these findings and to assess the impact of specific hemodynamic differences among the three THV platforms in the context of long-term clinical efficacy.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events and failure modes related to Impella CP: Insights from the FDA MAUDE database.","authors":"Kalyan R Chitturi, Ryan Wallace, Abhishek Chaturvedi, Ilan Merdler, Nauman Khalid, Brian C Case, Hayder D Hashim, Itsik Ben-Dor, Toby Rogers, Ron Waksman","doi":"10.1016/j.carrev.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.007","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hybrid coronary revascularization versus traditional coronary artery bypass grafting for left main coronary artery disease.","authors":"Elsa Hebbo, Madeleine Barker, Daniel A Gold, Malika Elhage Hassan, Mariem Sawan, Tanveer Rab, William J Nicholson, Michael E Halkos, Wissam A Jaber, Pratik B Sandesara","doi":"10.1016/j.carrev.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.02.004","url":null,"abstract":"<p><strong>Background: </strong>The current recommended intervention for significant left main (LM) stenosis, especially in patients with complex and high SYNTAX score disease, is coronary artery bypass grafting (CABG). Hybrid coronary revascularization (HCR) combines robotic coronary artery bypass and percutaneous coronary intervention, offering a less invasive approach for patients with LM disease.</p><p><strong>Objectives: </strong>We compare clinical outcomes between HCR and CABG in patients with LM disease.</p><p><strong>Methods: </strong>We retrospectively screened all patients treated for LM disease between 2019 and 2023 at a single institution. Propensity matching was used for baseline characteristics. The primary outcome was major adverse cardiovascular events (MACE) at 30 days, 6 months and 1 year. Secondary outcomes included death, myocardial infarction, repeat revascularization and stroke.</p><p><strong>Results: </strong>Out of a total of 761 patients treated for LM disease, 59 HCR patients were propensity matched to 59 CABG patients and were included in the final analysis. SYNTAX score was >33 for 49.1 % of HCR patients and 67.3 % of CABG patients (p = 0.15). Hospital length of stay was significantly shorter for HCR patients compared to CABG (4.07 days vs. 7.58 days, p < 0.001). MACE were significantly lower in the HCR group at 30 days (0 % vs 10.2 %; p = 0.01), 6 months (0 % vs 17 %; p = 0.002) and 1 year (2.4 % vs 20.5 %; p = 0.01) compared to CABG group. Additionally, there was a lower rate of repeat revascularization at 6 months in the HCR group (0 % vs 10.9 %; p = 0.02).</p><p><strong>Conclusions: </strong>This retrospective study demonstrates that HCR is a safe and viable alternative to CABG in patients with LM disease. Randomized clinical trials comparing the two treatment modalities are needed to confirm these findings.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}